Share this post on:

Product Name :
Zilovertamab

Search keywords :
ROR1

drugId :
null

Target Vo:
Inactive tyrosine-protein kinase transmembrane receptor ROR1

Target Vo Short Name :
ROR1

Moa_Name:
Inactive tyrosine-protein kinase transmembrane receptor ROR1 antagonists

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
University Of California San Diego

Active Company_Name :
Oncternal Therapeutics Inc

Active Indication_Name:
Lymphoma, B-Cell, Marginal Zone

In Active Indication_Name:
Lymphoma, B-Cell

Termination Status :

China Termination Status :

Highest Status:
Phase 2 Clinical

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Apitegromab Epigenetics
Hsp90 alpha Rabbit mAb site
RSK1 p90 Antibody (YA088): RSK1 p90 Antibody (YA088) is a non-conjugated and Rabbit origined monoclonal antibody about 83 kDa, targeting to RSK1 p90. It can be used for WB,ICC,IHC-P,FC assays with tag free, in the background of Human, Mouse, Rat.

Share this post on:

Author: Interleukin Related